Sansure Biotech(SH:688289) Sou Hu Cai Jing·2025-11-09 17:44Group 1 - The core point of the article highlights that Shengxiang Bio (688289) is actively expanding its investment in the AI medical application and innovative medical device sectors through a new fund, while also achieving significant product certifications [1][3]. Group 2 - On November 7, 2025, Shengxiang Bio's stock closed at 21.75 yuan, with a slight increase of 0.09% and a trading volume of 50,900 shares, amounting to a total transaction value of 111 million yuan [1]. - On the same day, the net outflow of main funds was 13.05 million yuan, accounting for 11.74% of the total transaction value, while retail investors saw a net inflow of 6.67 million yuan, representing 6.0% of the total [1][3]. Group 3 - Shengxiang Bio plans to invest 370 million yuan as a limited partner in a new medical industry fund with a target size of 1 billion yuan, focusing on AI medical applications and innovative medical devices [1][3]. - The company recently obtained three product certifications, including two Class III medical device registrations and one EU CE IVDR certification, for products related to the detection of Norovirus, Rotavirus, and EB virus [1][3].